Skip to content
Search

Latest Stories

Galen launches innovative medical food for PKU patients

Pharmaceutical firm Galen on Thursday launched an innovative medical food for people living with the rare, inherited metabolic disorder, phenylketonuria (PKU).

The PKU Easy Microtabs is an alternative to other protein substitutes on the market and will help patients from age 8 to manage the condition and consume the protein they need each day.


PKU Easy Microtabs are small coated microtabs containing non-Phe amino acids. They are swallowed with liquid or eaten with cold foods, such as jam or fruit puree.

Approximately 70 babies each year are born with PKU in the UK. The inherited disorder prevents the body from breaking down the proteins in foods to amino acids and if unmanaged, can lead to brain damage.

First launched by POA Pharma across Scandinavia in 2011, PKU Easy Microtabs was not available to UK patients via NHS until now. In January, Galen has announced the completion of its acquisition and takeover of POA Pharma.

Alongside its wider product portfolio, the move was intended to expand access to the company’s innovative nutritional therapies for people with PKU.

Dr Dennise Broderick, President & Managing Director at Galen, said: "Within one month of the completion of our acquisition of POA Pharma we are delighted to be able to bring this important new dietary management option to the 6,000 plus patients living with PKU across the UK.

"This is a condition that patients have to think about every single day of their lives to ensure they have the right levels of protein to function correctly. Portability, taste and digestion of medical foods are all important considerations that we are proud to have addressed for the community with our novel microtabs."

More For You

Trump signs executive order to accelerate US-based pharmaceutical manufacturing plants

US president Donald Trump

Pic credit: Getty Images

Trump signs executive order to encourage US drug manufacturing

US president Donald Trump signed an executive order on Monday that aims to reduce the time it takes to approve pharmaceutical plants in the country, as part of new regulations to encourage domestic manufacturing.

The order directs the US Food and Drug Administration to streamline reviews and work with domestic manufacturers to provide early support before facilities come online.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less
Many patients report inaccuracies or missing details in their NHS medical records

Inaccurate information can result in serious harm or even death, warns Healthwatch England.

Image Credit: Getty Images

1 in 4 adults have spotted errors in their NHS medical records, survey finds

Healthwatch England has raised the alarm over the risks posed by inaccurate medical records as research reveals widespread errors in NHS patient information.

Commissioned by Healthwatch England and conducted by BMG Research, the survey polled a representative sample of 1,800 adults in England between 24 and 27 March 2025.

Keep ReadingShow less